Catalano Michael A, Prasad Vikram, Spring Alexander M, Cassiere Hugh, Chang Tylis Y, Hartman Alan, Yu Pey-Jen
Division of Cardiovascular and Thoracic Surgery, Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY.
Department of Pathology, Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY.
JTCVS Open. 2020 Aug 3;4:36-42. doi: 10.1016/j.xjon.2020.07.009. eCollection 2020 Dec.
Heparin-induced thrombocytopenia (HIT) is an immune-mediated complication that occurs in a small percentage of patients exposed to heparin. Concerns of HIT are particularly high in patients undergoing cardiac procedures requiring cardiopulmonary bypass, as they are exposed to high doses of heparin intraoperatively. Our aim was to identify and assess the hospital courses of patients who were diagnosed with HIT during readmission following cardiac surgery.
A retrospective review of patients who underwent open cardiac surgical procedures from June 2017 through October 2019 was performed. Of these, we identified patients who were newly diagnosed with HIT upon readmission. HIT positivity was defined as a positive anti-PF4 antibody screening test, plus a positive serotonin release assay.
Of the 2496 patients identified, 13 patients were HIT positive on index admission and were excluded. Of the remaining 2483 patients, 351 were readmitted within 30 days. Six were newly diagnosed with HIT during readmission, 5 of whom presented with thrombotic complications. One patient was readmitted with thrombocytopenia and was started on argatroban; the remaining 5 did not have a significantly lower platelet count on readmission. Of the 12 patients readmitted for venous thromboembolism, 4 tested positive for HIT.
HIT can have a delayed appearance following open heart surgery. Venous thromboembolism appears to be a significant indicator for HIT during readmission, even in the absence of thrombocytopenia. This may support the use of non-heparin anticoagulation for cardiac surgery patients readmitted with thromboembolism until HIT status is determined.
肝素诱导的血小板减少症(HIT)是一种免疫介导的并发症,发生在一小部分接受肝素治疗的患者中。在需要体外循环的心脏手术患者中,对HIT的担忧尤为高,因为他们在术中会接触高剂量肝素。我们的目的是识别和评估心脏手术后再次入院时被诊断为HIT的患者的住院病程。
对2017年6月至2019年10月接受心脏直视手术的患者进行回顾性研究。其中,我们识别出再次入院时新诊断为HIT的患者。HIT阳性定义为抗PF4抗体筛查试验阳性,加上5-羟色胺释放试验阳性。
在识别出的2496例患者中,13例在首次入院时HIT阳性,被排除。在其余2483例患者中,351例在30天内再次入院。6例在再次入院时新诊断为HIT,其中5例出现血栓并发症。1例因血小板减少再次入院,开始使用阿加曲班治疗;其余5例再次入院时血小板计数没有显著降低。在因静脉血栓栓塞再次入院的12例患者中,4例HIT检测呈阳性。
心脏直视手术后HIT可能会延迟出现。静脉血栓栓塞似乎是再次入院时HIT的一个重要指标,即使在没有血小板减少的情况下也是如此。这可能支持对因血栓栓塞再次入院的心脏手术患者使用非肝素抗凝,直到确定HIT状态。